标题
Preclinical development of molecular-targeted agents for cancer
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 8, Issue 4, Pages 200-209
出版商
Springer Nature
发表日期
2010-12-07
DOI
10.1038/nrclinonc.2010.194
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer.
- (2010) HJ Burstein et al. CANCER RESEARCH
- Do We Have to Change the Way Targeted Drugs Are Developed?
- (2010) Alberto Ocana et al. JOURNAL OF CLINICAL ONCOLOGY
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
- (2009) A. K. Azab et al. BLOOD
- Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals
- (2009) Xiang H.-F. Zhang et al. CANCER CELL
- Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
- (2009) D. W. McMillin et al. CANCER RESEARCH
- Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
- (2009) T. Hay et al. CANCER RESEARCH
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
- (2009) Piyush B. Gupta et al. CELL
- Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
- (2009) Alberto Ocana et al. CURRENT DRUG TARGETS
- Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study
- (2009) Ian Chau et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice
- (2009) Tracy E. Strecker et al. JNCI-Journal of the National Cancer Institute
- In Vivo Imaging, Tracking, and Targeting of Cancer Stem Cells
- (2009) Erina Vlashi et al. JNCI-Journal of the National Cancer Institute
- Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors
- (2009) M Garayoa et al. LEUKEMIA
- Genes that mediate breast cancer metastasis to the brain
- (2009) Paula D. Bos et al. NATURE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic Lethality — A New Direction in Cancer-Drug Development
- (2009) J. Dirk Iglehart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
- (2009) Elizabeth Iorns et al. PLoS One
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
- (2008) E. M. Ocio et al. BLOOD
- Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
- (2008) Neil P. Shah et al. CANCER CELL
- Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
- (2008) Elizabeth Iorns et al. CANCER CELL
- Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
- (2008) C. S. Mitsiades et al. CANCER RESEARCH
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
- Translational research: are we on the right track?
- (2008) Charles L. Sawyers JOURNAL OF CLINICAL INVESTIGATION
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate
- (2008) Daniel P. Bradley et al. MAGNETIC RESONANCE IMAGING
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
- (2008) H Korkaya et al. ONCOGENE
- Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
- (2008) Qing-Bai She et al. PLoS One
- Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc 716 mice
- (2008) T. Fujishita et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations
- (2008) A. Dubrovska et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Co-evolution of tumor cells and their microenvironment
- (2008) Kornelia Polyak et al. TRENDS IN GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now